
Enable job alerts via email!
Generate a tailored resume in minutes
Land an interview and earn more. Learn more
A leading cancer treatment provider in Manchester is seeking a Clinical Oncologist to join their GU Disease Group. This role involves managing patients with prostate and bladder cancers, participating in clinical governance, and contributing to ongoing research efforts. The appointee will work closely with a multidisciplinary team, providing both radiotherapy and systemic therapies. Applicants should possess an RCR Fellowship or equivalent and have experience in GU cancers. This position offers an opportunity to engage in a dynamic and evolving environment focusing on innovative oncology treatments.
This replacement post is for 10 Programmed Activities (PAs) per week to provide oncology management and treatment within the Genito-Urinary (GU) Disease Group.
The Clinical Oncologist appointed will work with the GU team to provide a comprehensive clinical service for GU patients. This includes patients in the outpatient, inpatient and ambulatory settings, delivering Radiotherapy and Systemic Anti-Cancer Therapy (SACT) whilst also providing Clinical Oncology input to the GU MDT.
The GU Disease Group led by Professor Ananya Choudhury consists of 11 Clinical Oncologists. These oncologists manage all GU cancers diagnosed within the Greater Manchester and Cheshire Cancer Network, with many oncologists delivering a peripheral/Christie @ service through MDTs and clinics. Systemic therapy is delivered centrally or given to patients at peripheral or outreach clinics according to agreed protocols. Radiotherapy is delivered at The Christie or at our satellite units in Salford, Oldham and Macclesfield.
The group has an active prostate brachytherapy service, and the team has a strong commitment to research and trial activity in which the appointee would be expected to be involved in.
Systemic treatment for Germ Cell and renal is provided by the Medical Oncologist at the Christie
All Disease Group consultants work as part of a multi-disciplinary team supporting the delivery of this work including 5 Nurse Clinicians/Advanced Clinical Practitioners (including trainee's), 4.8 Clinical Nurse Specialists, 4 Clinical Research Fellows, 4 Specialist Trainees, 1 Pharmacist and 4.5 Research Nurses.
The appointee will serve the South Sector MDT which takes referrals from Stockport, Macclesfield and Tameside.
The urology group has an established record in radiotherapy related research with an internationally recognized programme of research. Radiotherapy-related research is led by Professor Ananya Choudhury and the urology team have monthly multi-disciplinary radiotherapy research meetings with regular attendance by radiographers, physicists and clinicians. There is also a monthly research seminar at which all ongoing research is presented by surgical, radiotherapy and systemic teams. Systemic and novel agent clinical trials are led by Dr A Hudson. The GU clinical oncology group has a broad clinical trial portfolio with phase I/II/III trials delivering research studies to ~150-200 patients per year.
The research team comprises 5 experienced research nurses and 6 clinical trials administrators.
The appointee will be encouraged to develop a research interest which may include the setting up of radiotherapy trials or clinical developments involving advanced radiotherapy techniques such as SABR, or MR Linac.
The Christie is one of Europe's leading cancer centres, treating over 60,000 patients a year. We are based in Manchester and serve a population of 3.2 million across Greater Manchester & Cheshire, but as a national specialist around 15% patients are referred to us from other parts of the country. We provide radiotherapy through one of the largest radiotherapy departments in the world chemotherapy on site and through 14 other hospitals highly specialist surgery for complex and rare cancer and a wide range of support and diagnostic services. We are also an international leader in research, with world first breakthroughs for over 100 years. We run one of the largest early clinical trial units in Europe with over 300 trials every year. Cancer research in Manchester, most of which is undertaken on the Christie site, has been officially ranked the best in the UK.
The role will be responsible for:
DUTIES AND RESPONSIBILITIESThe appointee will be expected to develop a significant urology interest delivering both radiotherapy and systemic therapy. The post involves four clinics, two seeing new patients and two for complex follow up patients. At present any patients requiring intravenous systemic therapy attend the Christie site to receive this treatment.
The appointee will serve the South Sector MDT which takes referrals from Stockport, Macclesfield and Tameside. This will include attendance at the specialist Urology MDT.
The South Sector uro-oncology MDT service is an established team comprising of clinical oncologists, urologists (performing level 2 surgery), pathologists, radiologists and clinical nurse specialists in addition to a MDT Co-ordinator.
The Clinical Oncology Urology group provide a comprehensive range of treatment options including VMAT/IGRT radiotherapy, LDR/HDR brachytherapy, prostate SABR, oligometastatic SABR and delivery of radionucleotide therapies e.g. Ra223. The provision of chemotherapy for prostate and urothelial cancers is also delivered by the clinical oncology team with renal cancer and testicular cancer systemic therapies undertaken by the medical oncology team.
The appointee will primarily be based at The Christie with the expectation that one clinic will be held at one of our Christie @ locations and will provide input to the following areas of delivery: Outpatient clinics - Providing support with waiting times across Greater Manchester and Cheshire Radiotherapy and SACT Services Inpatient Services - primarily Wards 4, 11, 12, 14 and 15 and the Oncology Assessment Unit Multi-Disciplinary Team meetings Team meetings Radiotherapy Peer Review Educational meetings Audit Urology Advanced Practitioner lead - supervisor SABR development Radionucleotide therapy lead
The postholder will be expected to see approximately ~200-300 new patients per year.
The appointee will have access to office accommodation and secretarial support.
The timetable below is indicative and will be confirmed on commencement in post.
This role does require participation in the on-call rota. The on-call rota involves a commitment to a full week (1: 20 rotation). The on-call consultant provides input to the acute admissions unit at the weekend.
Employer name
The Christie NHS FT
Clinical Oncology - E00084
Manchester
M20 4BX
Any attachments will be accessible after you click to apply.
413-MD-C2025-24583-OO-A